Stories
Indian Pharma Sector Set to Shift from Generics to Innovation-Led Growth
- •Industry leaders like Dilip Shanghvi, Kiran Mazumdar-Shaw, and Glenn Saldanha state India is ready to transition from a generic supplier to an innovation-driven pharmaceutical powerhouse.
- •Experts emphasize the need for sustained research and development investments, regulatory reforms, and strong ecosystem building over the next critical decade.
- •Innovative medicines represent a much larger global market share than generics, offering Indian companies massive opportunities for global expansion and competitiveness.
- •Leaders highlighted the importance of government schemes, scientific talent, and adopting advanced technologies like artificial intelligence to accelerate drug development and clinical trials.
Key Questions Answered
Industry leaders noted that the Indian pharmaceutical sector is well-positioned to transition into an innovation-driven industry, supported by strong scientific talent, growing financial strength, and supportive government policies. Executives like Dilip Shanghvi, Kiran Mazumdar-Shaw, and Glenn Saldanha emphasized that sustained R&D investments and regulatory reforms are key to this evolution.
Government initiatives such as the PRIP (Promotion of Research and Innovation in Pharma-MedTech Sector) scheme, BRIDGE, RDI, and Bioshakti programmes are designed to encourage pharmaceutical research and innovation across companies of different sizes.
Industry leaders highlighted the importance of establishing a strong regulatory framework to accelerate clinical research and drug development. Kiran Mazumdar-Shaw called for faster reforms to compress review timelines by using artificial intelligence and digital tools to move innovative products more quickly to patients.
